Greenwich LifeSciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Stockholders’ Equity (Details Narrative)

Stockholders’ Equity (Details Narrative) - USD ($)														1 Months Ended	12 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Nov. 13, 2025	Nov. 13, 2025	Dec. 24, 2024	Dec. 24, 2024	Jun. 13, 2024	Jun. 12, 2024	Jun. 22, 2022	Jan. 23, 2022	Oct. 19, 2021	Jan. 29, 2021	Dec. 22, 2020	Sep. 25, 2020	Jun. 22, 2020	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 19, 2024	Sep. 29, 2020	Sep. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted															893,181	893,181
Number of additional granted shares issued															120
Aggregate vested shares value															$ 2,009,657
Number of unvested shares															15,181
Unrecognized value of shares															$ 34,157
Stock repurchase expiration date								Mar. 31, 2023
Shares repurchased and cancelled																	519,828
Purchase price of shares repurchased and cancelled																	$ 7,536,216
Number of shares issued, value															$ 11,854,484	$ 1,869,111
Common stock, shares authorized															100,000,000	100,000,000
Common stock, par value															$ 0.001	$ 0.001
Issuance of common stock through partial exercise of underwriter warrants and gross proceeds									$ 562,596					$ 145,000
Proceeds from sale of shares																$ 2,499,998
IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds from sale of shares												$ 7,250,002
Underwriting discounts and commissions and offering expenses												$ 1,042,500
Number of shares issued												1,260,870
Public offering price												$ 5.75
Number of shares issued, value												$ 6,207,502
Exercised option to purchase of shares												189,130
Additional common shares issuable upon conversion of preferred stock																			42,404
Conversion price per share																			$ 5.75
Common stock, shares authorized																			100,000,000
Common stock, par value																			$ 0.001
Preferred stock, shares authorized																			10,000,000
Preferred stock, par value																			$ 0.001
IPO [Member] \| Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Converted shares of preferred stock into common stock																			1,520,937
IPO [Member] \| Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Converted shares of preferred stock into common stock																			129,267
IPO [Member] \| Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Converted shares of preferred stock into common stock																			66,575
IPO [Member] \| Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Converted shares of preferred stock into common stock																			305,990
Additional common shares issuable upon conversion of preferred stock																			42,404
Follow On Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds from sale of shares											$ 26,400,000
Number of shares issued											660,000
Public offering price											$ 40.00
Exercised option to purchase of shares											99,000
Net proceeds from sale of shares											$ 23,959,000
Net of underwriting discount commission and offering expenses											$ 2,441,000
Over-Allotment Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds from sale of shares										$ 2,800,000
Underwriting discounts and commissions and offering expenses										$ 252,000
Public offering price										$ 40.00
Exercised option to purchase of shares										70,000
Net proceeds from sale of shares										$ 2,548,000
Private Placement [Member] \| Chief Executive Officer and Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold					174,825
Shares sold price per share					$ 14.30
Proceeds from sale of shares						$ 2,499,998
ATM Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold															1,125,543	129,739
Shares sold price per share															$ 10.85	$ 15.92
Gross proceeds from sale of shares															$ 12,210,213	$ 2,065,366
Gross proceeds from sale of shares															11,854,484	1,869,111
Underwriting discounts and commissions and offering expenses															$ 355,729	$ 196,257
Amended and Restated Certificate of Incorporation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split													1-for-2.67
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock repurchase value								$ 10,000,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted															908,362	908,362
Common stock grant vested shares															0	0
Number of shares issued															1,125,543	129,739
Number of shares issued, value															$ 1,126	$ 130
Issuance of common stock through partial exercise of underwriter warrants, shares									80,696					20,174
Warrant [Member] \| IPO [Member] \| Aegis Capital Corp [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Public offering price												$ 6.9718
Warrants to purchase of common stock												100,870
Sale of shares percentage												8.00%
Warrants expiration date												Sep. 24, 2025
Warrant exercise price												$ 7.1875
Public offering price, percentage												125.00%
Warrants exercise price, percentage												97.00%
2019 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock capital shares reserved for future issuance																				1,500,000
2024 Amended Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock capital shares reserved for future issuance																		4,000,000
Additional common stock capital shares reserved for future issuance																		2,500,000
2019 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted							1,498,128
Exercise price							$ 7.63
Stock granted															$ 9,512,356
Risk-free rate															3.20%
Volatility rate															106.00%
Compensation expense															$ 8,382,760
Fair value															1,129,596	6,004,672
Two Thousand Twenty Four Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted	100,000		1,627,937
Exercise price		$ 8.20	$ 12.16
Stock granted	$ 626,469														$ 16,190,565
Risk-free rate	3.70%														4.50%
Volatility rate	101.00%														103.00%
Compensation expense	$ 626,469														$ 8,674,007
Fair value															$ 7,516,558	$ 4,875,239
Number of options vested and expected to vest			100,000	100,000
Vesting rights percentage				25.00%											75.00%
Vesting term															3 years